Nav: Home

Collaboration aims to reduce racial and ethnic disparities in clinical trials

March 21, 2019

DETROIT - Spencer Hoover, vice president and executive director of the Henry Ford Cancer Institute, is co-author of a manuscript published in the Journal of Oncology Practice aimed at establishing best practices to promote diversity in clinical trials. In-depth interviews were conducted with leaders from U.S. cancer centers with above average recruitment of racial and ethnic minority groups into clinical trials, with the goal of identifying specific strategies that were used to facilitate participation among racial and ethnic minorities.

Participation of racial and ethnic minority groups in cancer trials is disproportionately low despite a high-prevalence of certain cancers among those populations. According to the National Institute on Minority Health and Health Disparities, approximately 10 percent of the minority population in the U.S. participates in clinical trials. At the Henry Ford Cancer Institute, more than 30 percent of cancer clinical trial participants represent a racial or ethnic minority group.

"The importance of engaging racial and ethnic minority patients in clinical trials cannot be overstated," said Hoover. "This population of patients has long been underrepresented in clinical trials, and it's time we change that. Clinical trials for medications and medical devices must be representative of the diverse populations who will use them."

The manuscript indicates leadership, patient engagement, and community engagement practices as crucial factors to facilitate increased accrual of racial and ethnic minorities in cancer trials. In particular, high-recruiting centers such as Henry Ford Cancer Institute excelled in engaging with providers as the most important influencer of patient participation, engaging community leaders and building trust, and seeking dedicated input clinical research programs from racial and ethnic minority patients and caregivers to identify and overcome potential barriers as early as possible.

"There are few cancer centers in the U.S. that are able to engage ethnic and racial minority patients in clinical trials as effectively as the Henry Ford Cancer Institute," said Jeanne Regnante, senior vice president of Community Education at Sustainable Healthy Communities, LLC and lead author of the manuscript. "Our hope is that cancer centers throughout the country will benefit from the best practices identified in this publication. Leadership at the Henry Ford Cancer Institute is clearly laying the foundation of a paradigm-shift with precision medicine, especially in cancer."
To learn more about clinical trials at the Henry Ford Cancer Institute, visit

Henry Ford Health System

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...